Ruth M Escalona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5779665/publications.pdf

Version: 2024-02-01

759233 940533 16 651 12 16 citations h-index g-index papers 16 16 16 1058 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology, 2004, 228, 1-21.	3.2	127
2	Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Seminars in Cancer Biology, 2018, 53, 265-281.	9.6	127
3	Fetal Testis Dysgenesis and Compromised Leydig Cell Function in Tgfbr3 (Betaglycan) Knockout Mice1. Biology of Reproduction, 2010, 82, 153-162.	2.7	63
4	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Frontiers in Oncology, 2014, 4, 75.	2.8	62
5	Loss of Betaglycan Contributes to the Malignant Properties of Human Granulosa Tumor Cells. Molecular Endocrinology, 2009, 23, 539-548.	3.7	51
6	Inhibins Differentially Antagonize Activin and Bone Morphogenetic Protein Action in a Mouse Adrenocortical Cell Line. Endocrinology, 2006, 147, 3462-3471.	2.8	43
7	Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Scientific Reports, 2016, 6, 30061.	3.3	33
8	Transforming Growth Factor- \hat{l}^2 Blocks Inhibin Binding to Different Target Cell Types in a Context-Dependent Manner through Dual Mechanisms Involving Betaglycan. Endocrinology, 2007, 148, 5355-5368.	2.8	29
9	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer, 2020, 20, 960.	2.6	21
10	Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Scientific Reports, 2017, 7, 46312.	3.3	18
11	Prostaglandin E and F Receptor Expression and Myometrial Sensitivity at Labor Onset in the Sheep1. Biology of Reproduction, 2005, 72, 937-943.	2.7	17
12	Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in L \hat{I}^2 T2 gonadotropes. Molecular and Cellular Endocrinology, 2009, 307, 149-156.	3.2	17
13	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 450.	4.1	13
14	Effects of TGFbeta2 on Wild-Type and Tgfbr3 Knockout Mouse Fetal Testis1. Biology of Reproduction, 2013, 88, 66.	2.7	12
15	Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment. Frontiers in Oncology, 2021, 11, 796588.	2.8	12
16	Labor-Associated Regulation of Prostaglandin E and F Synthesis and Action in the Ovine Amnion and Cervix. Journal of the Society for Gynecologic Investigation, 2006, 13, 19-24.	1.7	6